Developing an eVLP mRNA vaccine for respiratory syncytial virus with enhanced pre-fusion targeting humoral responses.

ABSTRACT: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract disease (LRTD) in infants, the elderly, and immunocompromised individuals. In this study, we leveraged the innovative EABR (ESCRT- and ALIX-binding region) vaccine technology to develop a pre-fusion (Pre-F)-based RSV mRNA vaccine (Pre-F-EABR) that encodes self-assembling enveloped virus-like particles (eVLPs). In vitro expression of Pre-F-EABR mRNA manifested pronounced Pre-F protein expression, particularly on cell membranes and in cell culture supernatant, compared to classical Pre-F and Pre-F-Ferritin nanoparticle (Pre-F-Fe) mRNAs, suggesting efficient eVLP self-assembly. Immunization of mice with lipid nanoparticle-encapsulated, nucleoside-modified mRNAs (mRNA-LNPs) demonstrated that the Pre-F-EABR v

SUBMITTER: Sun L 

PROVIDER: S-EPMC12548431 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature